Eli Lilly's Taltz-Zepbound Combo Delivers 27.1% Clearance and ≥10% Weight Loss at 36 Weeks
Eli Lilly's Phase 3b TOGETHER-PsO trial found 27.1% achieved skin clearance and ≥10% weight loss at 36 weeks with Taltz plus Zepbound versus 5.8% on Taltz alone. GLP-1 market is projected to grow from $23.88B in 2026 to $33.26B by 2030 (8.6% CAGR), driven by oral and long-acting therapies.
1. Phase 3b TOGETHER-PsO Trial Results
On February 18, Eli Lilly reported topline data from its Phase 3b TOGETHER-PsO trial in adults with moderate-to-severe plaque psoriasis and obesity. At the 36-week assessment, 27.1% of patients on Taltz plus Zepbound achieved both complete skin clearance and at least 10% body weight reduction, versus 5.8% with Taltz monotherapy.
2. GLP-1 Market Outlook
The global GLP-1 market is forecast to expand from $23.88 billion in 2026 to $33.26 billion by 2030, reflecting an 8.6% compound annual growth rate. Innovations in oral formulations and long-acting peptide therapies are key drivers that could bolster Lilly’s obesity and diabetes portfolio.
3. Safety Profile and Next Steps
The combination therapy’s safety profile matched known effects of each drug, with mild-to-moderate nausea, diarrhea and injection site reactions reported. Lilly intends to engage regulatory authorities on a submission pathway for the Taltz-Zepbound regimen, aiming to offer a differentiated treatment for psoriasis patients with concurrent obesity.